There’s A Simple Way To Feel Happier, According To The New Science Of Emotion : Shots – Health News – NPR

Back in the fall, Michelle Shiota noticed she wasn't feeling like herself. Her mind felt trapped. "I don't know if you've ever worn a corset, but I had this very tight, straining feeling in my mind," she says. "My mind had shrunk."

Shiota is a psychologist at Arizona State University and an expert on emotions. When the COVID-19 crisis struck, she began working from home and doing one activity, over and over again, all day long.

"I will be honest, for the past 14 months, I have spent most of my waking hours looking at a screen, either my laptop, my phone or a TV screen," she says, often from the same sofa, in the same room in her San Francisco home. All that isolation and screen time had taken a toll on Shiota.

During the pandemic, many people have felt their mental health decline. The problem has hit essential workers and young adults, ages 18 to 24, the worst, the Kaiser Family Foundation reported in May. The percentage of adults with signs of anxiety or depression has grown threefold, from about 10% to 30%.

Although some people are starting to test the waters of public life again, planning vacations and socializing more, others may still have lingering signs of what psychologists call languishing. They may feel an emptiness or dissatisfaction in day-to-day life. Or feel like they're stuck in weariness or stagnation.

Luckily, an emerging area of brain science has a new way to help lift yourself out of languishing and bring more joy into your life. It worked for Shiota.

"I had to expand my consciousness," she says. And she did it by intentionally cultivating a particular emotion.

Explore ways to cultivate well-being with NPR's Joy Generator.

For thousands of years, there's been a common belief in Western culture about emotions that they are hard-wired and reflexive, psychologist Lisa Feldman Barrett writes in the book How Emotions Are Made: The Secret Life of the Brain. "When something happens in the world ... our emotions come on fast and uncontrollable, as if somebody flipped a switch," she writes.

But when researchers look at what's going on inside the brain and inside the body during specific emotional states, the theory doesn't hold up.

Over the past decade, neuroscientists have begun to shift how they think emotions arise. Rather than being inevitable, hard-coded experiences, researchers now think emotions are malleable, and people have more influence over them than previously thought.

Say for example, you're walking in the woods, and you see a grizzly bear, says neuroscientist Anil Seth at the University of Sussex. "You recognize it's a bear," he says, "and then what happens?"

Previously researchers thought the emotion comes first. "You see a bear and then you feel afraid," Seth says. "Because you're afraid, your brain then jacks up your adrenaline levels."

Your heart rate rises. Your breath quickens. Your pupils dilate. And blood rushes to your skeletal muscles. The old theory was that "the fear sets in train all kinds of flight and fight responses so that you are well-prepared to run away and live another day," he adds. In other words, the emotion (i.e., fear) triggers the physiological responses (i.e., an adrenaline rush).

But according to the latest research, the human body probably works the other way around, Seth says. "The brain registers a grizzly bear, and that perception sets in train all the physiological responses." You get an adrenaline rush. Your heart rate goes up. You start breathing faster. Blood rushes to your muscles. And then the emotion comes.

The brain senses these physiological changes and decides which emotion to conjure up. The emotion is an interpretation of what's going on both inside the body (the adrenaline rush) and the outside of the body (the sight of the bear). "The brain has to figure out what caused the sensory signals," Seth says.

The chosen emotion not only helps the brain make sense of these signals, but it also helps the brain predict better the immediate future and how to handle the situation at hand. Which emotion would be most useful? Which emotion will help me survive?

To figure that all out, Seth says, the brain uses one more piece of information and this part is key. The brain takes into account your past experiences, your memories.

Let's return back to that encounter with the grizzly bear. If your past experiences with bears come largely through news reports of attacks and maulings, then your brain will likely interpret your bodily sensations raised heart rate, raised blood pressure, sweaty palms as fear. Lots of fear! And this emotion will help drive you away from the bear. "So you can live another day," Seth says.

But what if your family hunts for a living? And your past encounters with a bear ended in a wonderful feast for you and your neighbors. Then your brain may interpret the adrenaline rush the heavy breathing and raised heart rate as excitement. This positive emotion will help drive you forward toward the bear, while all the physiological changes help you bring home dinner.

"Your brain uses memories from the past in order to create the present," says Barrett, who also does neuroscience research. "It's bringing knowledge from the past to make sense of the immediate future, which then becomes your present."

Neuroscientists call this "the predictive brain." Understanding how these predictions work is "very powerful knowledge," Barrett says. It means that emotions aren't hard-wired reactions to particular situations, which are out of your control (i.e., you see a bear and therefore you must feel afraid). But rather it's the opposite. "You can, in fact, modify what you feel in very direct ways," she says.

It's not about trying to force a happier or less fearful feeling in the moment, Barrett says. But rather, it's all about planning ahead. You can stack the deck in favor of your brain, choosing positive, uplifting emotions in two major ways, she says.

The first one is a no-brainer: You can take care of your body physically. According to this new theory, the brain constructs emotions based largely on physiological signals and other sensations from your body. So by boosting your physical health, you can decrease the chance your body will send unpleasant signals to your brain and, in turn, increase the chance, your brain will construct positive emotions instead of negative ones. "You can get more sleep. You can eat properly and exercise," she says.

The second approach to influencing your emotions may be less familiar but likely just as impactful: You can "cultivate" the emotions you want to have in the future.

"If you know that your brain uses your past in order to make sense [of] and create the present, then you can practice cultivating [positive] emotions today so that your brain can automatically use that knowledge when it's making emotions tomorrow," Barrett says.

By practicing particular emotions, you can "rewire" your brain, she says. "Your brain grows new connections that make it easier for you to automatically cultivate these emotions in the future." So when you start to feel a negative emotion, such as sadness or frustration, you can more easily swap that negative feeling for a positive one, such as awe or gratitude.

"For example, when I am video chatting with somebody in China, I can feel irritated very easily when the connection isn't very good," Barrett says. "Or I can feel awe at the fact that someone can be halfway around the world, and I can see their face and hear their voice, even if it is imperfect, and I can be grateful for that ability."

In this way, emotions are a bit like muscle memory. If you practice the finger patterns for a chord on the piano, a few minutes each day, eventually your fingers can play those chords with little thought. The chords become second nature.

The same goes for emotions. To help pull out of the pandemic blues, it's time to start "practicing" positive emotions and it won't take as much as learning all the chords.

All you need is about five to 10 minutes, says psychologist Belinda Campos at the University of California, Irvine. "Hopefully it wouldn't take people as much effort as it does to eat healthier or to exercise," she says. "Positive emotions feel good. I think people will find them rewarding enough to return to them and keep doing them."

Scientists say this practice is helpful to prevent or work with everyday doldrums and weariness. It isn't intended as a replacement for treatments, such as counseling and medication, for serious mood disorders or anyone going through intense or prolonged bouts of depression.

A few decades ago, scientists used to lump together all kinds of positive emotions into one concept: happiness. Since then, a group of psychologists, including Campos and Shiota, figured that there is a whole "family tree" of positive emotions, including pride, nurturant love, contentment, nostalgia, flow, gratitude and awe.

One reason these emotions often make us feel good is they shift our focus away from the self that is "me and my problems" and onto others, Campos says. "They help put the self in its balanced place, of not being absolutely the highest thing on the to-do list. They help us focus on the joys that relationships can bring."

She adds, "In this way, positive emotions are part of what helps you to put others before the self." And helping others often makes people feel good. "So, for example, people report levels of higher well-being when they're giving to others, and it can feel better to be on the giving end rather than the receiving end," she says. "I think that's more evidence that focusing on others can be really good for us."

The idea of cultivating positive emotions is pretty simple. Choose one of these emotions and then do a specific action regularly that helps evoke it. Psychologists have devised suggestions for how to get started, but it can be as simple as taking time to notice and appreciate the small things around you that uplift you. (Read three tips to get started at the end of this piece.)

Over time, your brain will start to use these emotions more often and turn to negative emotions less frequently.

Take, for instance, gratitude.

For the past year and a half, Dr. Sriram Shamasunder has been on the front lines of the COVID-19 pandemic. Shamasunder is a physician at the University of California, San Francisco, and he spends about half his time in low-income communities around the world.

To help bring more "light" into his life, Shamasunder started to keep a gratitude journal. It was part of a project for the Greater Good Science Center at the University of California, Berkeley.

Each day, Shamasunder simply jotted down things around him for which he was grateful. "So not necessarily spending a whole lot of time racking my mind, but just everyday occurrences that were powerful or meaningful or just simple and beautiful," Shamasunder told The Science of Happiness podcast. He jotted down the doctors and nurses working on Sunday, "the unseen hands who created a vaccine," "the evening light, magical and orange and blue," and a tree outside that provides refuge to birds, ants and squirrels.

By intentionally cultivating gratitude, for even a short period each day, Shamasunder found it easier to evoke positive feelings throughout the day. "The act of naming the gratitudes carried into the next day and the next, where I became more aware of things in my life that I should cherish in the moment, or I need to cherish."

Back in the fall, when Shiota, the Arizona State psychologist, felt her mind shrinking, she knew exactly which emotion she needed to cultivate.

She got up off the couch, drove West from her San Francisco home and ended up at the edge of the ocean. "I am trying to reconnect with the vast natural world, with the universe beyond my professional and personal responsibilities, and beyond this moment in time," Shiota writes in the Annals of the New York Academy of Sciences. "I am searching for awe."

Shiota is a world expert on awe. She says the emotion is difficult to define, "but I think that what we are dealing with is a change that happens in our mind and in our bodies and in our feelings when we encounter something so extraordinary that we can't explain it."

That encounter can be with something grand, such as a panoramic view of a red sun dipping into the Pacific Ocean. It can be with something minuscule, such as the black spots on a ladybug. (How did they get so perfectly round?) It can be a scent, a taste or sound. "It can be a very complex and powerful song that you've never heard before or even a scene in a TV show," Shiota says.

Whatever it is, the extraordinariness of the event makes you pause, for a bit, Shiota says, and try to figure it out. How does a rose smell like a lemon? Why does a perfectly ripened peach taste so good? "We simply slow down our body, slow down," Shiota says.

And this pause calms your body. "I've found evidence that the activation of our fight-flight sympathetic nervous system dials back a little bit."

The feeling of awe also widens your perspective, she says which Shiota desperately needed after spending so much time looking at screens. "I had to consciously force myself to look further away. I had to let my senses my sight, my sound, take in a broader scope of what was going on around me."

In addition to going to the beach, Shiota also simply walked around her neighborhood, looking for unexpected and inspiring things.

"There was this amazingly elaborate, chalk drawing in recognition of somebody's birthday. There was a couple, in which one person was clearly helping the other learn to roller-skate on the San Francisco hills. And they're clinging on to each other for dear life," she says with a chuckle. "Then the flowers! If you look closely at flowers, in a way that you never take the time to do, you'll see how incredibly intricate they are.

"So the opportunities for awe are there," she says. "Look for what moves you, what pushes your sense of boundaries of what is out there in the world."

It took a little time and patience Shiota says, but eventually these "awe walks" helped her recover from her pandemic funk. Practicing awe released her mind from that constraining "corset."

"Then my mind was able to spread out and take up the space that it needs to take to feel OK," she says. And once her mind released, her body followed. "When you take off the corset, your whole body goes, 'Oh, oh! That's much better.' "

Psychologists say you can improve your well-being if you recognize moments of positive feelings, value them and seek them out more often. Below, find a few other ideas for cultivating positive emotions and turning happiness into a habit. To explore more ideas, check out NPR's Joy Generator.

1) Share some appreciation: Campos recommends this simple practice. Get together with some friends and write out on cards three things that you're grateful for in the other person. Then share the cards with each other.

"We're using this task right now in my laboratory, and it seems to be very evocative of positive emotion," she says. And though the data is preliminary, she says, "what we see so far is that people enjoy writing what they appreciate in others, and they enjoy sharing it with the other person. It seems to be affirming bonds." Sometimes it even ends in hugs.

2) Take an awe walk: Take a five-minute walk outside each day where you intentionally shift your thoughts outward. Turn off your cellphone or even better don't bring it with you. "Focus your attention on small details of the world around you," psychologist Piercarlo Valdesolo at Claremont McKenna College suggests. Look for things that are unexpected, hard to explain and delightful.

For example, take a moment and find a crack in the sidewalk, where a weed is poking out, Barrett says. And let yourself feel awe at the power of nature. "Practice that feeling over and over again," she says. "Practice feeling awe at colorful clouds, an intricate pattern on a flower or the sight of a full moon."

3) Listen to a calm concert: A recent meta-analysis from the University of Michigan found that sounds of nature, including birdsongs and water sounds, lower stress, promote calmness and improve mood. Find a bench in your neighborhood under a tree or near water. Sit down, close your eyes and consciously listen to the natural sounds around you. Listen for birdsongs, rustling wind or trickling water. Try sitting for at least five minutes whenever you get a chance. Allow and enjoy calm to wash over you.

Here is the original post:
There's A Simple Way To Feel Happier, According To The New Science Of Emotion : Shots - Health News - NPR

Cancer and the Heart; COVID and Dx Delays; Not the Same Old Accelerated Approval? – MedPage Today

The European Society of Cardiology has launched a clinical trial to evaluate cardiac MRI during chemotherapy to prevent treatment-related heart failure in patients with cancer.

A large retrospective study showed that patients with heart failure had a significantly increased risk of developing cancer. (ESC Heart Failure)

The American Heart Association awarded $11 million in grants to support research into disparities in cardio-oncology.

Patients with relapsed/refractory large B-cell lymphoma had significantly better event-free survival if they received the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) instead of chemotherapy plus stem cell transplantation, Kite announced.

More evidence that the COVID-19 pandemic led to delays in cancer diagnosis and cancer-related surgery. (Journal of the National Cancer Institute)

Patients with multiple myeloma had highly variable responses to two doses of mRNA COVID-19 vaccination. (Cancer Cell)

"There is no reason why people cannot do randomized studies to get the drugs approved," said Richard Pazdur, MD, of the FDA's Oncology Center of Excellence, during an advisory committee meeting, possibly signaling a change of direction for the agency's accelerated approval process for cancer drugs. (Endpoints News)

A type of laser surgery for early-stage bladder cancer may help reduce surgical complications and the risk of recurrence. (Cedars-Sinai Medical Center)

Exelixis and Ipsen announced that the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) significantly improved progression-free survival as first-line treatment for advanced liver cancer.

A phase III trial of the chemokine receptor antagonist balixafortide plus eribulin for previously treated advanced HER2-negative breast cancer showed no improvement in the co-primary endpoint of objective response rate or the key secondary endpoint of clinical benefit rate versus eribulin alone, Polyphor announced.

Historically, prostate cancer responds poorly to immunotherapy, but a new study suggests a fourth of prostate cancers have molecular characteristics favorable for treatment with immune checkpoint inhibitors. (Clinical Cancer Research)

Assisted reproduction techniques did not increase subsequent risk of cancer in children and young adults. (European Society of Human Reproduction and Embryology)

Puma Biotechnology announced expanded FDA approval of neratinib (Nerlynx) to include both early-stage and metastatic HER2-positive breast cancer.

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

See the original post here:
Cancer and the Heart; COVID and Dx Delays; Not the Same Old Accelerated Approval? - MedPage Today

Limits for human embryo research have been changed : This calls for public debate – Down To Earth Magazine

The new regulation makes it possible to conduct research on human embryos that are at more advanced stages of development

For 40 years, research into early human development has been guided by the principle that after 14 days, an embryo should not be used for research and must be destroyed. This rule has been part of the law of more than 12 countries. But new guidelines released by the International Society for Stem Cell Research have removed this rule. This makes it possible to conduct research on human embryos that are at more advanced stages of development.

Now, countries must revise their laws, policies and guidelines to reflect this change. But first, public debate is crucial to determine the limits of what sort of research should be allowed.

Over the decades human embryo research has allowed us to understand normal and abnormal human development, as well as early genetic diseases and disorders. Studying human embryos, as the earliest forms of human life, can give us insight into why miscarriages occur, and how our complex body systems develop. Human embryos are also important for stem cell research, where researchers try and create cell-based therapies to treat human diseases.

Often, extra embryos are created during in-vitro fertilisation procedures. These extra embryos may be donated for research. They are cultured (or grown) in a laboratory and can be studied until they reach day 14 post-creation.

The 14-day rule has served as an international standard since 1990 when it was included in the Human Fertilisation and Embryology Act in the United Kingdom. At the time that it was introduced, it was not possible to keep human embryos alive in a laboratory for more than a few days. However, scientists have been recently been able to keep embryos alive for longer periods, between 12 and 13 days. The ethical, legal and social consequences of such research were also important considerations.

The 14-day rule and the new guidelines

Although the 14-day rule has been criticised as being arbitrarily decided, there are a number of reasons for the time frame.

After an egg cell is fertilised by a sperm cell, the resulting embryo consists of a few identical cells. Most embryos will implant in the uterus after the 14th day. After this point, the primitive streak appears, which is the first sign of an embryos developing nervous system. The rule also identified the point at which the embryo shows signs of individuation, because it is no longer possible for the embryo to split into twins after 14 days. Some people reason that due to these events, it is at this stage that a moral being comes into existence, and it would not be ethical to perform research on embryos after this time.

There has been increasing pressure from some researchers to remove the 14-day rule, or at least extend it, as it prevents critical research from being undertaken. Extending the rule would allow important research into early human development to be done. The new guidelines make it possible to do research on embryos older than 14 days if the approval processes of the relevant ethics committees are followed.

A significant problem, however, is that there is no longer any limit on the time frame for research. Would it be permissible to do research on human embryos that are 20 days old or 40 days old? The guidelines specify no limit. The longer a human embryo is allowed to grow, the more recognisably human it becomes. At what point would we regard the research unethical, and at what point does the moral cost outweigh the benefits of research?

What the law says

Countries around the world take a variety of approaches to human embryo research. Some like Italy and Germany dont allow it at all. Others, like the UK, allow research to continue until the embryo is 14 days old, after which it must be destroyed. There are also some which permit embryo research without identifying a limit. Some, like the United States, do not have any law regulating it (but there are guidelines which contain reference to the 14-day rule).

In South Africa, reference to the rule is found in the National Health Act (2003), which states that human embryo research may only be done with permission of the minister, and that the embryos must not be older than 14 days.

International guidelines are not legally binding. But the effect of the revised guidelines is that the international standard for best practice in scientific research has now changed. This means that countries which have implemented the rule in their laws will need to revise them so that they are in line with best practice in science.

The future of human embryo research

Human embryo research is a sensitive topic because people are divided on the moral status of the human embryo. Some people believe that the embryo, as the earliest form of human life, should be protected and not subjected to research at all. Others believe that while an embryo has some moral status, it cannot be protected in the same way as humans are, and may be used for some important research which could ultimately benefit people.

The decision to discard the 14-rule appears to have been made without public input. That does not encourage the public to trust in science, and public engagement should have come before such an an important rule was changed.

There are a number of approaches to working with the revised guidance. Bioethicist Franoise Baylis has suggested that project-specific time limits should be identified, based on the minimum amount of time required to address the stated research objectives. This would mean that some research would still be subject to the 14-day limit, while other studies would be permitted to exceed it. Another approach would be to keep the 14-day limit as the norm, and consider applications to exceed it case by case. Or the limit could be extended to 28 days.

The coming conversations surrounding embryo research will prove to be very important. The proverbial genie is out of the bottle, and public debate is crucial.

Sheetal Soni, Researcher, Lecturer, Attorney, University of KwaZulu-Natal

This article is republished from The Conversation under a Creative Commons license. Read the original article.

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Read more:
Limits for human embryo research have been changed : This calls for public debate - Down To Earth Magazine

NPR’s Ina Jaffe Shared Her Breast Cancer Journey, Couple Moves Up Their Wedding After Cancer Diagnosis and More – Curetoday.com

NPR correspondent Ina Jaffe wrote about her journey with breast cancer.

Ina Jaffe, a correspondent for NPR, penned an essay about her journey with stage 4 metastatic breast cancer.

I've been keeping a secret. I've decided to tell it, she began.

Jaffe shared that she received her diagnosis two years ago and refrained from sharing it with friends or strangers because she was still in the hysterical stage.

Because, faced with an incurable cancer diagnosis, I did what any normal person would do: I stopped sleeping. I stopped eating. I sobbed a lot. I was grieving for my own life, she wrote.

Eventually, she told 50 of her closest friends and three editors at NPR who also kept the secret per her request. This past week, she decided to publicly share the news in hopes of helping others and expressing her outrage.

Up to 30% of women with early-stage breast cancer progress to stage 4, Jaffe said. I thought that you were more likely to get metastatic breast cancer if you'd been diagnosed with a more-advanced stage of breast cancer to begin with. Wrong again. It's not dependent on your stage at original diagnosis. I was stage 1B when I was first diagnosed in January 2012.

She also explained that she had a titanium rod implanted in her thigh to deal with a bone metastasis and brain radiation, among other treatments.

Carene and Cameron Hughes exchanged their vows on Sunday after moving up their wedding, which was originally scheduled for August. The couple had to push the wedding up because doctors found a tumor on Camerons pancreas, as well as two lesions on the liver. The cancer is stage 4.

I didnt want the memories of our wedding to be me rolling down the aisle in a wheelchair or something like that, I wanted it to be a memory she could have, and kids could have, even after Im gone, Cameron Hughes told WXII 12 News.

The Hughes and their four children still have hope that a clinical trial at Duke University could make a difference, but are taking the news one day at a time.

Dont take life for granted. You know, Im 51 and Ive lived a pretty good life. Theres things I want to see that I may not get to see, so live life, be happy, love, one love, Cameron Hughes said.

Children who are born through assisted reproductive technology (ART), such as in vitro fertilization, intracytoplasmic sperm injection and frozen embryo transfer, do not have an increased risk of cancer. The research was presented at the European Society of Human Reproduction and Embryology annual meeting this week.

The results are "quite reassuring, especially for children conceived by IVF, and are an important contribution to the current knowledge about health risks in ART-offspring," study author Dr. Mandy Spaan, of Amsterdam University Medical Center and the Netherlands Cancer Institute, told U.S. News.

The study may help doctors communicate better about any potential health risks for future children of patients who are considering fertility treatments. It will also provide gynecologists with "evidence-based information about the association between ART and cancer risk in children and adolescents," said Spaan in a news release.

Trey Mancini, a Baltimore Orioles player who missed the entirety of the 2020 season after a stage 3 colon cancer diagnosis, recently accepted an invitation from Major League Baseball to participate in the Home Run Derby.

This season was Mancinis return to baseball after undergoing treatment for the cancer. He is consistently among baseballs best in maximum exit velocity, according to ESPN.

Mancinis cancer was initially found just days after the spring training season had been shut down due to the COVID-19 pandemic. At 29, he never expected to receive the diagnosis his father, 58, had received a few years prior.

There were times early on when I wasnt entirely sure Id be playing baseball again, Mancini told MLB. I'd be lying if I'd say that was the first thing that came to mind. The whole time I just wanted to be healthy long-term and live a long life. And baseball definitely was on the back burner when I was going through all that.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Go here to read the rest:
NPR's Ina Jaffe Shared Her Breast Cancer Journey, Couple Moves Up Their Wedding After Cancer Diagnosis and More - Curetoday.com

COVID Infection Unlikely to Jeopardize IVF Success, Small Study Suggests – MedPage Today

Women who were previously infected with COVID-19 did not have decreased chances of success with assisted reproduction treatment, according to a small observational study.

Among a cohort of 46 patients with prior SARS-CoV-2 infection, there were no significant differences in average anti-Mullerian hormone (AMH) levels before and after they got sick (1.73 vs 1.61 ng/ml, respectively), reported Maria Cruz Palomino, PhD, of the IVI Madrid fertility clinic.

For women with a normal ovarian reserve, AMH levels -- which indicate a woman's ovarian reserve status -- declined from 4.6 to 3.1 ng/ml. However, this decrease was unlikely to compromise a patient's ability to produce eggs for fertilization, said Palomino during her presentation at the European Society of Human Reproduction and Embryology annual meeting.

"Generally, the data showed no variation in AMH levels before and after SARS-CoV-2 infection," Palomino said in a press release. "We could assume that the chances of success in [patients'] fertility treatment remained intact."

Palomino added that while the researchers did observe a small drop in AMH levels among recovered COVID-19 patients with normal ovarian reserve, the decrease likely would not affect the chances of achieving pregnancy, and may not even be attributed to SARS-CoV-2 infection.

Albert Hsu, MD, an assistant professor of clinical ob/gyn at the University of Missouri in Columbia, who was not involved in this study, said that while these findings provide some information about SARS-CoV-2 and fertility, more data are needed before stating that COVID-19 infection does not impact chances of IVF success. Additionally, Hsu stated that AMH levels, which the study authors used to indicate ovarian reserve status, may not actually convey how likely it is for in vitro fertilization (IVF) patients to conceive.

"Anti-Mullerian hormone is a great predictor of how many eggs I am going to get when I stimulate a woman with IVF," Hsu told MedPage Today. "It very much does not predict pregnancy."

Because SARS-CoV-2 binds to the ACE-2 receptor, which is widely expressed in the ovaries, some have raised concerns about how COVID-19 infection might affect ovarian reserve, Palomino's group stated. However, initial studies have shown no correlation between COVID-19 and loss of fertility in reproductive-age women.

In this study, Palomino and colleagues recruited patients from 11 clinics in Spain who had IVF between May and June of 2020. All 46 study participants had documented baseline hormone levels before receiving a positive test for COVID-19.

Researchers analyzed AMH levels as an indicator of their response to fertility treatment. Around 16 participants had a low ovarian reserve (AMH <1 ng/ml), and 30 had normal ovarian reserve status (AMH 1 ng/ml). The average age for patients with low and normal ovarian reserve was 39 and 35, respectively.

AMH levels remained stagnant in women with low ovarian reserve, from 0.8 ng/ml before infection to 0.7 ng/ml afterward.

Palomino and colleagues emphasized that this was a small study, and is not robust enough to inform public health recommendations. Additionally, because this is an observational study, results are limited by potential confounding.

Amanda D'Ambrosio is a reporter on MedPage Todays enterprise & investigative team. She covers obstetrics-gynecology and other clinical news, and writes features about the U.S. healthcare system. Follow

Read more:
COVID Infection Unlikely to Jeopardize IVF Success, Small Study Suggests - MedPage Today

Spatial Genomics & Transcriptomics Market Analysis by Size, Trends, Share, Key Country, Opportunities, Growth, Emerging Technologies, And Regional…

Technological advancements in sequencing technologies, increasing application of spatial genomics and transcriptomics in biomarker identification and drug discovery, and increasing funding to expand R&D activities are key factors driving revenue growth of market

Market Size USD 178.4 Million in 2020, Market Growth at a CAGR of 18.1%, Market Trends Increasing prevalence of genetic disorders globally

The Global Spatial Genomics & Transcriptomics Market size is expected to reach USD 675.34 Million by 2028 at a CAGR of 18.1% over the forecast period, according to the latest report by Reports and Data. Key factors driving market revenue growth include increasing prevalence of genetic disorders and chronic conditions such as cancers, neurological disorders, and rare diseases, which have boosted need for high-resolution multiplex assays and instruments, and this is expected to further drive developments in spatial-based technologies. Increasing application of spatial genomics and transcriptomics for drug discovery and biomarker identification is also a key factor expected to drive revenue growth of market over the forecast period. Significant funding to expand R&D activities in the field of spatial-based technology is expected to support market growth going ahead.

Ask for Sample Report @ https://www.reportsanddata.com/sample-enquiry-form/3964

Spatial transcriptomics covers methods specifically designed to assign cell types to their specific locations across tissue samples. It allows determination of subcellular localization of mRNA molecules. Data obtained about spatial distribution of mRNA molecules allows researchers to study cellular heterogeneity in tissues, tumors, and immune cells. Spatial-profiling based solutions allows analysis of tissue microenvironment, tumor biology, and tissues biomarkers. Spatial genomics and transcriptomics offers key insights in the fields of oncology, immunology, cell and gene therapy, histology, and embryology.

Spatial genomics and transcriptomics are novel research fields that aim to fill the knowledge gap about cellular machinery, spatial organization, differentiations, and localization that occurs at genomic and transcriptomics level within each cell and in tissues. These techniques have significant potential in managing chronic and rare diseases and rising burden of chronic disease such as cancers and diabetes across the globe have boosted their application in drug discovery and development. This is expected to fuel revenue growth of market over the forecast period. However, lack of skilled professionals and low awareness about advanced spatial-based technologies can restrain market growth to a significant extent over the forecast period.

Some Key Highlights from the Report:

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3964

For the purpose of this report, Reports and Data has segmented the global spatial genomics & transcriptomics market based on technique, product application, end-use industry, and region:

Technique Outlook (Revenue, USD Million; 2018-2028)

Product Outlook (Revenue, USD Million; 2018-2028)

Application Outlook (Revenue, USD Million; 2018-2028)

End-user Outlook (Revenue, USD Million; 2018-2028)

Regional Outlook (Revenue, USD Million; 2018-2028)

Connect with an expert for customization of Report @ https://www.reportsanddata.com/request-customization-form/3964

Reasons to invest in this report:

Thank you for reading our report. Customization of the report is available based on the clients requirements. For more details, kindly connect with us, and our team will ensure the report is suited to meet your requirements.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John WHead of Business DevelopmentDirect Line: +1-212-710-1370E-mail: sales@reportsanddata.comReports and Data | Web: https://www.reportsanddata.comNews: http://www.reportsanddata.com/market-newsConnect with us: Facebook | LinkedIn | Twitter

See more here:
Spatial Genomics & Transcriptomics Market Analysis by Size, Trends, Share, Key Country, Opportunities, Growth, Emerging Technologies, And Regional...

IU researchers developing noninvasive brain stimulation technique to treat neurological disorders – News-Medical.Net

Indiana University School of Medicine researchers are developing a new, noninvasive brain stimulation technique to treat neurological disorders, including pain, traumatic brain injury (TBI), epilepsy, Parkinson's disease, Alzheimer's disease and more.

Given the increasing use of brain stimulation in human brain study and treatment of neurological diseases, this research can make a big impact on physicians and their patients."

Xiaoming Jin, PhD, associate professor of anatomy, cell biology and physiology

When someone experiences a brain injury, nerve injury, or neurodegeneration, such as in epilepsy and TBI, there is damage to the brain which can lead to loss and damage of nerve or neurons and development of hyperexcitability that underlies some neurological disorders such as neuropathic pain and epilepsy.

"The conventional treatment is mainly to try to directly inhibit such hyperexcitability," Jin said, "but we found the initial damage of the brain or nerve system was caused by a loss of brain tissue, which causes the nervous system to compensate for loss of function by working harder, so we need to stimulate activity instead of inhibit it."

The technique, described in a newly published paper in Neurotherapeutics, uses a new type of magnetoelectric nanoparticles that can be delivered to a specific part of the brain using a magnetic field. After, a magnetic wave can be emitted to stimulate neural activity in that particular part of the brain. The method is noninvasive, good for stimulating deep brain function and is more efficient than traditional methods of brain stimulation, without the need for genetic manipulation.

"This is the only new type of nanoparticle that allows us to effectively stimulate the brain without doing any invasive procedures," Jin said. "We can inject the nanoparticle as a solution into the vein and then bring it to any part of the body. When you apply a magnet on the head, you can localize and deliver the nanoparticle to the targeted brain region."

The team has been working on the technique for five years in collaboration with the University of Miami and hopes to begin studying the method in humans in the next couple of years. The study has received funding from the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, National Science Foundation, as well as the Indiana Clinical and Translational Sciences Institute (CTSI), which helped provide funding for a medical neuroscience graduate student, Tyler Nguyen, to participate in the research. Read the full published paper in Neurotherapeutics.

Source:

Journal reference:

Nguyen, T., et al. (2021) In Vivo Wireless Brain Stimulation via Non-invasive and Targeted Delivery of Magnetoelectric Nanoparticles. Neurotherapeutics. doi.org/10.1007/s13311-021-01071-0.

Visit link:
IU researchers developing noninvasive brain stimulation technique to treat neurological disorders - News-Medical.Net

Insights on the High Content Screening Global Market to 2026 – by Product, Application, End-user and Region – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global high content screening market exhibited strong growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of 8.2% during 2021-2026.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations. It is an integration of modern cell biology, flow cytometry and robotic handling that involves fluorescence imaging for analyzing various biochemical and physical characteristics of the sample cells. This aids in drug discovery, complex multivariate drug profiling and toxicity studies, while utilizing robots, detectors and software to monitor the entire process.

The increasing prevalence of neurodegenerative diseases across the globe, such as Alzheimer's and Parkinson's, is one of the key factors driving the market growth. The rising need for cost-effective drug discovery systems in the pharmaceutical industry is also providing a boost to the market growth. In comparison to the traditionally used methods, HCS solutions prove to be inexpensive and resource- and time-efficient for analyzing the potential toxicity of chemicals and complex substances. Advancements in informatics solutions and imaging instruments are acting as another growth-inducing factor. HCS equipment manufacturers are producing innovative equipment that is integrated with software platforms and artificial intelligence (AI) systems to enhance the visualization capabilities of the devices. In line with this, the development of automated systems for analyzing cell separation and scalability has further enhanced the adoption of HCS technology. Other factors, including the rising geriatric population and increasing investments in the research and development (R&D) of advanced screening systems, are projected to drive the market further.

Companies Mentioned

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global High Content Screening Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product

7 Market Breakup by Application

8 Market Breakup by End-User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Indicators

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/73fef0

Continue reading here:
Insights on the High Content Screening Global Market to 2026 - by Product, Application, End-user and Region - ResearchAndMarkets.com - Business Wire

Protein That Puts the Brakes on Fat Burning Could Be Obesity Drug Target – Weill Cornell Medicine Newsroom

A protein called Them1 prevents fat burning in cells by blocking access to the fuel source, according to preclinical research by Weill Cornell Medicine, NewYork-Presbyterian and Harvard Medical School/Beth Israel Deaconess Medical Center investigators. The findings may contribute to the development of a new type of obesity treatment that targets this response.

When cold temperatures force mice to ramp up fat burning to generate heat, they produce an enzyme that sits on standby, ready to shut down energy-intensive heat production when the need has passed, according a study published June 9 in Nature Communications. The study was a collaboration between Dr. David Cohen, chief of the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medicine, and cell biology and microscopy expert Dr. Susan Hagen, associate professor of surgery at Harvard Medical School.

The study explains a new mechanism that regulates metabolism, said Dr. Cohen. Them1 hacks the energy pipeline and cuts off the fuel supply to the energy-burning mitochondria.

Dr. Cohen and his colleagues first became interested in Them1 about a decade ago when they discovered cold mice produce a lot of the enzyme in their brown fat tissue. They knew mice were using brown fat tissue to generate heat, so they assumed that Them1 was helping to produce heat. To prove this, they genetically engineered mice lacking Them1 to see what would happen.

To our complete surprise, when you delete the gene for Them1, the mouse produces more heat, not less, he said. In fact, the mice lacking the gene for Them1 burned so much energy trying to make heat that they ate twice as much as a typical mouse and still lost weight.

The new study helps explain how Them1 turns off heat production. In the experiments, the team used light and electron microscopy to observe Them1 in action in mouse brown fat cells grown in the laboratory. The experiments showed that when the cells are stimulated to burn fat using a drug, a phosphate group is added to Them1. The chemical modification causes Them1 molecules to spread out throughout the cell. This frees cellular powerhouses called mitochondria to efficiently turn the cells fat stores into energy. But when the stimulation stops, the Them1 molecules quickly reorganize like a protein flash mob into a membrane-less structure situated between the mitochondria and the fats they use as fuel, which stops energy production.

Humans also have brown fat and produce more Them1 in cold conditions, so the findings may have exciting implications for the treatment of obesity. Dr. Cohen and his colleagues are already working to develop an anti-obesity drug that inhibits Them1.

If we could give humans a drug that inactivates Them1s energy expenditure-suppressing activity, we might be able to increase fat burning, Dr. Cohen said.

Read more:
Protein That Puts the Brakes on Fat Burning Could Be Obesity Drug Target - Weill Cornell Medicine Newsroom

Protein Aggregation Diseases | In the Pipeline – Science Magazine

If you have occasion to study neurodegeneration, you will be struck by how many terrible high-profile diseases in this area seem to share a common theme. Alzheimers, ALS, progressive supranuclear palsy, Parkinsons, Lewy body dementia, some types of frontotemporal dementia, Huntingtons, prion diseases such as BSE and more all feature abnormal protein aggregates that appear in neural tissues. There are plenty of variations, naturally. These aggregates happen in different types of cells, involve different key proteins that seem to have a variety of structural features that lead them into this process, and the resulting diseases affect different regions of the brain. But the overlap of such aggregation with disease is impossible to ignore, and believe me, no one has been ignoring it.

Ever since Alois Alzheimer noticed what we now call amyloid plaques in the brains of deceased dementia patients over a hundred years ago, every advance in neuroscience, cell biology, and instrumentation has been brought to bear on this problem. And its a measure of how complex such diseases are that we still dont truly understand whats going on and we still have no disease-modifying treatments for any of them. Were still not sure how many of these aggregates are direct causes of the associated diseases, and how many might be side effects of some other disease process thats more proximal. Even the ones where we have the most detailed knowledge have escaped us Huntingtons for example. In that case, the protein that aggregates (Huntingtin) does so because it has a long tail of glutamine residues. This genetic basis for the disease was made clear in 1993. We know that if there are fewer than 28 of these, a patient will be completely normal. 28 to 35 of them takes you into a range where some signs might be picked up by post-mortem histopathlogy, but the affected patient is still asymptomatic. 36 to 40 glutamine repeats, thats a danger zone. Patients in this range show disease, but its severity, age of onset, and progression are variable. And greater than 40 repeats means full-blown, progressive, and fatal Huntingtons.

Isnt that enough clues? If this were a movie, the screenwriters would have us running into the labs with a cure in the third act, for sure. But were not even sure if the biggest problem in the disease is the amino acid repeats in the protein or the trinucleotide repeats in the precursor RNA. Even if we were absolutely sure that all we needed to do was to keep the Huntingtin protein from sticking to itself, we still cant manage that. Drug discovery organizations have been screening for aggregation inhibitors for decades now, and I have seen more papers than I can possibly remember on compounds that (theoretically) keep amyloid, tau, Huntingtin, alpha-synuclein, and other such proteins from aggregating. To the best of my knowledge, most of these have not even made it into clinical trials, and the ones that do have a flat zero per cent success rate. On the other end of the process, Alzheimers especially has seen a whole list of attempts to clear out such aggregates, especially before they become pathological, but as my recent hand-wringing about aducanumab should make clear, I dont see any successes so far in that approach, either.

This short review paper (open access) urges everyone to realize that these aggregates are even more complicated than they look. From one perspective thats not such cheerful news, but were always better off facing reality in these situations. Its easier to think of protein aggregation as happening with single proteins that have something wrong with them that form relatively pure clumps that are then cytotoxic. In vitro screening efforts often assume a picture something like this there are a lot of systems where aggregation of protein constructs (usually through formation of fibril structures) is used as the basis for such a screen, and one recommendation I take from this new paper is to just stop doing that sort of thing entirely.

Thats because, as numerous references show, these aggregates in vivo are far from homogeneous lumps of toxic protein. Amyloid plaques, neurofibrillary tangles, and Lewy bodies have hundreds of different proteins in them. They have varying amounts of lipids, RNA species, and carbohydrates as well, and were not very far along in characterizing these. Lewy bodies have entire membranous organelles tangled up in them! The lack of detailed knowledge is partly because of the sheer complexity of the problem, and partly (as with the carbohydrates) because of deficiencies in our techniques for analyzing such things in general.

We also have deficiencies with some of the tools used in cell biology studies. Watching protein fibrils form from purified starting materials can tell you a lot from a structural biology perspective, but its not the same as whats happening inside a neuron. Indeed, the structures of the fibrils themselves are different. One of the things I took from this paper is that my picture of the formation of the in vivo protein aggregates is way off its easy, especially for a chemist, to imagine something like a messy precipitation, with random clumps of stuff coming out of solution. But in reality, these things are probably forming under rather specific and controlled conditions, and it may be really hard to recapitulate these outside of the cell. The details of the various post-translational modification of the aggregated proteins also argue for specific conditions rather than random fallout.

Even studying them inside the cell is tricky. Close study by advanced microscopy in wild-type cells and tissues shows that the structure and composition of even a single type of aggregate can vary according to what compartment of the cell it appears in, although these may appear superficially similar. As the paper points out, using protein overexpression systems leads to unnatural artifacts, as can tagging the relevant proteins with fluorescent groups. Youre always worried about such effects, of course, but when the very process youre highlighting seem to depend on self-association of a key protein, then such assays are at their most vulnerable. At any rate, we have to rework our approaches here, because continuing to use (over)simplified assays mainly because theyre doable does not seem to be getting us very far.

Nobody likes to hear the Gosh, its more complicated than we thought news, but we get to hear it a lot in this business, and its generally an accurate view of the situation. Once in a great while its less complicated than we though, and those are memorable occasions, but mostly its like this when you study the causes of disease. Especially in neurology! The important thing is not to use this as an excuse to throw up your hands, but rather as a call to find something that can be improved.

Originally posted here:
Protein Aggregation Diseases | In the Pipeline - Science Magazine